Joseph McClanaghan

815 total citations
5 papers, 59 citations indexed

About

Joseph McClanaghan is a scholar working on Cancer Research, Molecular Biology and Neurology. According to data from OpenAlex, Joseph McClanaghan has authored 5 papers receiving a total of 59 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Cancer Research, 2 papers in Molecular Biology and 2 papers in Neurology. Recurrent topics in Joseph McClanaghan's work include Neuroblastoma Research and Treatments (2 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Acute Myeloid Leukemia Research (1 paper). Joseph McClanaghan is often cited by papers focused on Neuroblastoma Research and Treatments (2 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Acute Myeloid Leukemia Research (1 paper). Joseph McClanaghan collaborates with scholars based in United States, United Kingdom and Japan. Joseph McClanaghan's co-authors include Cyril H. Benes, Patricia Greninger, Regina K. Egan, Giovanna T. Stein, Byunghee Yoo, Anna Moore, Zdravka Medarova, Anthony C. Faber, Jeffrey A. Engelman and Jennifer E. Koblinski and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Joseph McClanaghan

5 papers receiving 59 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph McClanaghan United States	4	42	27	13	12	9	5	59
Ruth Witt Germany	4	40 1.0×	12 0.4×	12 0.9×	22 1.8×	9 1.0×	7	65
Shiyong Ma China	5	37 0.9×	7 0.3×	3 0.2×	3 0.3×	3 0.3×	10	60
Brittney Gordon United States	3	36 0.9×	15 0.6×	16 1.2×	9 0.8×	23 2.6×	5	59
Jill D. Kremer United States	5	30 0.7×	14 0.5×	24 1.8×	8 0.7×	15 1.7×	11	58
William Yang United Kingdom	4	32 0.8×	13 0.5×	16 1.2×	6 0.5×	2 0.2×	4	59
Stéphanie Vasseur France	4	33 0.8×	22 0.8×	29 2.2×	5 0.4×	9 1.0×	7	60
Siebe Loontiens Belgium	5	19 0.5×	6 0.2×	9 0.7×	2 0.2×	6 0.7×	10	39
Daniel Jachimowicz Sweden	4	60 1.4×	55 2.0×	6 0.5×	10 0.8×	8 0.9×	4	78
Kevin S. Kapner United States	3	56 1.3×	42 1.6×	21 1.6×	3 0.3×	11 1.2×	6	88
Christian Lawerenz Germany	2	28 0.7×	19 0.7×	7 0.5×	2 0.2×	7 0.8×	2	42

Countries citing papers authored by Joseph McClanaghan

Since Specialization

Citations

This map shows the geographic impact of Joseph McClanaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph McClanaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph McClanaghan more than expected).

Fields of papers citing papers by Joseph McClanaghan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph McClanaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph McClanaghan. The network helps show where Joseph McClanaghan may publish in the future.

Co-authorship network of co-authors of Joseph McClanaghan

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph McClanaghan. A scholar is included among the top collaborators of Joseph McClanaghan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph McClanaghan. Joseph McClanaghan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Cai, Jinyang, Sheeba Jacob, Richard Kurupi, et al.. (2022). High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell Reports. 40(4). 111095–111095. 10 indexed citations

2.

Lochmann, Timothy L., Konstantinos V. Floros, Richard Kurupi, et al.. (2021). Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma. Proceedings of the National Academy of Sciences. 118(13). 18 indexed citations

3.

Carvajal, Luis A., David Sutton, Joseph McClanaghan, et al.. (2019). Abstract C064: The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent. Molecular Cancer Therapeutics. 18(12_Supplement). C064–C064. 2 indexed citations

4.

Dastur, Anahita, Carlotta Costa, August Williams, et al.. (2018). NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Clinical Cancer Research. 25(1). 312–324. 16 indexed citations

5.

Yoo, Byunghee, Patricia Greninger, Giovanna T. Stein, et al.. (2018). Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin. PLoS ONE. 13(7). e0201046–e0201046. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact